Biotech: Page 58
-
Novo strikes $110M deal for regulatory fast pass
The Danish drugmaker will buy a priority review voucher from Marinus Pharmaceuticals, the latest in a string of similarly priced purchases.
By Ned Pagliarulo • July 15, 2022 -
CytomX lays off staff, joining growing list of biotechs restructuring
A shaky biotech market has forced another drugmaker to adjust, with CytomX revealing plans to reduce its workforce by 40%.
By Delilah Alvarado • July 14, 2022 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
koto_feja via Getty Images
Atara shares sink after update on multiple sclerosis trial
Much-anticipated interim results from Atara’s Phase 2 study revealed little about the likelihood of the trial’s success, spurring a market sell-off.
By Ned Pagliarulo • July 13, 2022 -
Jonathan Gardner/BioPharma Dive
Agios CEO to step down, handing role to veteran in rare disease drug sales
A former Celgene executive, Jackie Fouse has led Agios since 2019, overseeing its transformation into a company focused solely on uncommon diseases. In August, she will transition to chair its board of directors.
By Jacob Bell • July 12, 2022 -
National Institute of Allergy and Infectious Diseases/NIH. (2019). "Activated Eosinophils" [Micrograph]. Retrieved from Flickr.
Bain Capital backs new biotech startup developing oral asthma drug
Areteia Therapeutics will receive $350 million from Bain and others to advance a drug that was previously licensed to Biogen for testing as an ALS treatment.
By Delilah Alvarado • July 12, 2022 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
Moderna founder launches Apriori with $50M to stay ahead of virus variants
Flagship Pioneering’s latest startup aims to use predictive technology to find “variant-proof” treatments and vaccines for infectious diseases before they might be needed.
By Delilah Alvarado • July 11, 2022 -
Courtesy of Vertex Pharmaceuticals
Vertex acquires another maker of potentially curative diabetes treatments
For $320 million, Vertex said it plans to buy ViaCyte in a deal that would provide “complementary assets, capabilities and technologies” to the ones it picked up through the 2019 acquisition of Semma Therapeutics.
By Jacob Bell • July 11, 2022 -
Md Saiful Islam Khan via Getty Images
Healthcare asset manager Innoviva buys another biotech at a bargain price
Two months after acquiring Entasis Therapeutics, the firm reached a deal to buy La Jolla Pharmaceutical Co. at a fraction of what La Jolla was worth just a few years ago.
By Jonathan Gardner • July 11, 2022 -
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
AbbVie dials back partnership on experimental Alzheimer's drug
While AbbVie is bailing on one of the two programs it paid Alector $205 million to acquire five years ago, work will continue on the second project. That drug, however, has shown safety signals.
By Jonathan Gardner • July 8, 2022 -
400tmax via Getty Images
Radius, fending off activists, outlines pitch for $890 million buyout
The biotech detailed the process that led to its take-private offer last month, aiming to win the support of shareholders, including two firms that have pushed for change.
By Ben Fidler • July 8, 2022 -
Courtesy of Vertex Pharmaceuticals
Vertex, continuing its rebound, cleared to resume testing of diabetes cell therapy
The FDA’s decision is the latest boost for a company whose shares have climbed more than 30% during the biotech sector’s worst downswing in years.
By Ben Fidler • July 6, 2022 -
atiatiati via Getty Images
Two cancer biotechs merge, raise cash as sector-wide downturn continues
Syros Pharmaceuticals and Tyme Technologies, shares of which trade near all-time lows, will combine and raise about $130 million in the latest example of how the industry’s slump is affecting publicly traded biotechs.
By Delilah Alvarado • July 5, 2022 -
Permission granted by Seagen
Seagen strengthens case for cancer drug as buyout rumors swirl
New study results support the potential use of its breast cancer medicine Tukysa, part of a wide-ranging alliance with rumored buyer Merck & Co., in advanced colorectal cancer.
By Ben Fidler • July 5, 2022 -
Courtesy of CureVac
CureVac sues rival COVID-19 vaccine maker BioNTech for patent infringement
The biotech, whose own efforts to develop a COVID-19 vaccine have faltered, claims its inventions were crucial to the development of BioNTech’s top-selling coronavirus shot.
By Jonathan Gardner • July 5, 2022 -
Christopher Furlong via Getty Images
With $100M AstraZeneca deal, a biotech and its investors engineer another buyout
An entity originally known as Teneobio has now been the focus of three acquisition deals with large pharmaceutical companies since 2021, capitalizing on the industry’s growing interest in dual-acting antibody drugs.
By Ben Fidler • July 5, 2022 -
Kena Betancur via Getty Images
Crunching the numbers on the first half drought for biotech IPOs
Data compiled by BioPharma Dive show a growing gap in the frequency and size of new offerings compared to prior years. Some analysts believe as many as a third of public biotechs must “go away” before the sector’s slump ends.
By Ben Fidler • July 1, 2022 -
libre de droit via Getty Images
Bayer, Amgen back ReCode's plan to broaden genetic medicine's reach
The two drugmakers joined a long list of investors, including Pfizer and Sanofi, that have been funding the startup’s plan to develop a new type of lipid nanoparticle technology.
By Delilah Alvarado • June 29, 2022 -
Arch brings in another $3B for biotech startup investing
The venture firm’s largest-ever haul comes about a year and a half after it raised another $2 billion and amidst an historic downturn for the sector.
By Jacob Bell • June 29, 2022 -
Permission granted by Relay Therapeutics
Relay details new research plans in quest to design better cancer drugs
The biotech company revealed three new drug candidates for breast cancer, while laying out a path to regulators for its most advanced treatment.
By Ned Pagliarulo • June 27, 2022 -
Permission granted by Biogen
Biogen, citing insurance challenges, shutters one of its Aduhelm studies
The company says a recent coverage decision by Medicare has forced it to end an observational trial of the Alzheimer's drug after enrolling just 29 participants.
By Jacob Bell • June 22, 2022 -
Courtesy of Galapagos
Galapagos, with latest deals, charts an unexpected journey to cell therapy
The Belgian drugmaker will spend more than $100 million to acquire two companies, CellPoint and AboundBio, in a move meant to “disrupt” CAR-T treatment.
By Jacob Bell • June 22, 2022 -
Getty / Edited by BioPharma Dive
A biotech startup launches with $38M to develop a cystic fibrosis gene therapy
Carbon Biosciences believes its technology, which is based on parvoviruses, could allow for larger gene delivery and repeat dosing.
By Delilah Alvarado • June 21, 2022 -
E+ via Getty Images
Boehringer extends cancer dealmaking with right to buy biotech partner
The German pharma company has secured an option to acquire Trutino Biosciences, two years after inking a research collaboration with the San Diego drug developer.
By Delilah Alvarado • June 16, 2022 -
Spencer Platt via Getty Images
With biotech in retreat, Third Rock raises $1B for life sciences investing
The fund, Third Rock’s sixth, comes amid a significant downturn in biotech stocks, which has raised questions about the viability of young drug startups.
By Jacob Bell • June 15, 2022 -
Meletios Verras via Getty Images
Vertex, CRISPR strengthen case for pioneering gene-editing treatment
Positive data from 75 patients with either sickle cell disease or beta thalassemia keep the companies’ therapy on track to become the first CRISPR-based treatment submitted to drug regulators, possibly by the end of the year.
By Jacob Bell • June 11, 2022
Previous
